AR116721A1 - Soluciones oromucosas de zolpidem o sales farmacéuticamente aceptables de los mismos - Google Patents

Soluciones oromucosas de zolpidem o sales farmacéuticamente aceptables de los mismos

Info

Publication number
AR116721A1
AR116721A1 ARP190102862A ARP190102862A AR116721A1 AR 116721 A1 AR116721 A1 AR 116721A1 AR P190102862 A ARP190102862 A AR P190102862A AR P190102862 A ARP190102862 A AR P190102862A AR 116721 A1 AR116721 A1 AR 116721A1
Authority
AR
Argentina
Prior art keywords
zolpidem
pharmaceutically acceptable
formulations
solutions
oromucous
Prior art date
Application number
ARP190102862A
Other languages
English (en)
Inventor
Asheel K Patel
Kush M Patel
Milan R Patel
Ketan R Patel
Nisheel K Patel
Original Assignee
Troikaa Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Troikaa Pharmaceuticals Ltd filed Critical Troikaa Pharmaceuticals Ltd
Publication of AR116721A1 publication Critical patent/AR116721A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente se refiere a formulaciones bucales o sublinguales de Zolpidem o una sal farmacéuticamente aceptable del mismo. Las formulaciones minimizan la cantidad de potenciadores de la penetración y, sin embargo, proporcionan una rápida penetración transmucosal del fármaco. Estas formulaciones no solo proporcionan la concentración deseada (0.5% a 10% p/v) del medicamento en forma de solución transparente (clara), sino que también logran formulaciones estables durante toda la vida útil de al menos aproximadamente 2 años. El pH de las soluciones estables no acuosas de la presente está en el intervalo de pH 5 a 9, preferiblemente de 6 a 9, más preferiblemente de 7 a 9.
ARP190102862A 2018-10-08 2019-10-08 Soluciones oromucosas de zolpidem o sales farmacéuticamente aceptables de los mismos AR116721A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201821038060 2018-10-08

Publications (1)

Publication Number Publication Date
AR116721A1 true AR116721A1 (es) 2021-06-09

Family

ID=68296607

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190102862A AR116721A1 (es) 2018-10-08 2019-10-08 Soluciones oromucosas de zolpidem o sales farmacéuticamente aceptables de los mismos

Country Status (26)

Country Link
US (1) US20220000845A1 (es)
EP (1) EP3863604A1 (es)
JP (1) JP2022501407A (es)
KR (1) KR20210074311A (es)
CN (1) CN112996488A (es)
AR (1) AR116721A1 (es)
AU (1) AU2019358394A1 (es)
BR (1) BR112021006551A2 (es)
CA (1) CA3115195A1 (es)
CL (1) CL2021000856A1 (es)
CO (1) CO2021005969A2 (es)
DO (1) DOP2021000060A (es)
EA (1) EA202190765A1 (es)
EC (1) ECSP21024213A (es)
GE (1) GEP20237492B (es)
IL (1) IL282020A (es)
JO (1) JOP20210068A1 (es)
MA (1) MA53050B1 (es)
MX (1) MX2021003975A (es)
PE (1) PE20211007A1 (es)
PH (1) PH12021550748A1 (es)
SG (1) SG11202103255RA (es)
TN (1) TN2021000051A1 (es)
UY (1) UY38405A (es)
WO (1) WO2020075183A1 (es)
ZA (1) ZA202102322B (es)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7632517B2 (en) 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
EP2042161A1 (en) 1997-10-01 2009-04-01 Novadel Pharma Inc. Propellant-free spray composition comprising anti-emetic agent
JP2006516963A (ja) * 2003-02-04 2006-07-13 クリサリス テクノロジーズ インコーポレイテッド エアロゾル製剤及びブスピロン、ブプレノルフィン、トリアゾラム、シクロベンザプリン及びゾルピデムのエアロゾル送出
GB0329918D0 (en) * 2003-12-24 2004-01-28 West Pharm Serv Drug Res Ltd Intranasal compositions
CA2556450C (en) * 2004-02-17 2013-08-06 Transoral Pharmaceuticals, Inc. Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
US7658945B2 (en) * 2004-02-17 2010-02-09 Transcept Pharmaceuticals, Inc. Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
GB0423800D0 (en) 2004-10-27 2004-12-01 Orexo Ab New pharmaceutical formulations
JP5577021B2 (ja) * 2005-02-17 2014-08-20 アボット・ラボラトリーズ 動物における障害を治療および予防するための薬剤組成物の経粘膜投与
BRPI0609984A2 (pt) * 2005-05-25 2010-05-18 Transcept Pharmaceuticals Inc uso de zolpidem ou um sal do mesmo
CA2649895C (en) * 2006-04-19 2013-03-26 Novadel Pharma Inc. Stable hydroalcoholic oral spray formulations and methods
WO2008141264A1 (en) * 2007-05-10 2008-11-20 Novadel Pharma Inc. Anti-insomnia compositions and methods
CN101842079B (zh) * 2007-08-31 2012-09-05 阿基米德开发有限公司 非水性药物组合物
US20090246256A1 (en) * 2008-03-27 2009-10-01 Al-Ghananeem Abeer M Compositions and Methods for Transmucosal Delivery of Lofexidine
CN101780038A (zh) * 2010-03-30 2010-07-21 上海现代药物制剂工程研究中心有限公司 酒石酸唑吡坦口腔喷雾剂及其制备方法
PE20131492A1 (es) * 2010-10-12 2014-01-17 Ivax Pharmaceuticals Ireland Dispositivo pulverizador nasal

Also Published As

Publication number Publication date
MA53050A1 (fr) 2022-06-30
MA53050B1 (fr) 2023-03-31
ZA202102322B (en) 2023-01-25
CN112996488A (zh) 2021-06-18
BR112021006551A2 (pt) 2021-07-06
ECSP21024213A (es) 2021-06-30
PE20211007A1 (es) 2021-06-01
MX2021003975A (es) 2021-05-27
AU2019358394A1 (en) 2021-05-06
DOP2021000060A (es) 2021-08-31
EP3863604A1 (en) 2021-08-18
JP2022501407A (ja) 2022-01-06
US20220000845A1 (en) 2022-01-06
EA202190765A1 (ru) 2021-07-01
WO2020075183A1 (en) 2020-04-16
UY38405A (es) 2020-03-31
JOP20210068A1 (ar) 2023-01-30
TN2021000051A1 (en) 2022-10-03
CO2021005969A2 (es) 2021-05-20
PH12021550748A1 (en) 2022-02-14
KR20210074311A (ko) 2021-06-21
IL282020A (en) 2021-05-31
CL2021000856A1 (es) 2021-09-24
GEP20237492B (en) 2023-04-10
SG11202103255RA (en) 2021-04-29
CA3115195A1 (en) 2020-04-16

Similar Documents

Publication Publication Date Title
UY37998A (es) Agentes antivirales contra la hepatitis b
CO2018010748A2 (es) Agentes antivirales contra la hepatitis b
UY37997A (es) Agentes antivirales contra la hepatitis b
UY38059A (es) Heterociclos sustituidos como agentes antivirales
CO2020002980A2 (es) Agentes antivirales contra la hepatitis b.
CY1119025T1 (el) Συνδυασμος δυο αντιιικων για την αγωγη της ηπατιτιδας c
AR072261A1 (es) Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos.
PE20171345A1 (es) Modificador del sabor dulce
JP2014094963A5 (es)
PE20141855A1 (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
UY38383A (es) Heterociclos funcionalizados como agentes antivirales
CY1106055T1 (el) Τυποποιηση των υποκατεστημενων βενζιμιδαζολων
DOP2013000243A (es) Inhibidores sustituidos de acetil-coa carboxilasa
PE20130379A1 (es) Metodos para el tratamiento de las ulceras del pie diabetico
MX2020004930A (es) Compuestos de biarilo sustituido novedosos como inhibidores de indolamina 2,3-dioxigenasa (ido).
PE20191486A1 (es) COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CANCER
ECSP19026973A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
CO2022008690A2 (es) Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso
UY36546A (es) “ciclopropabenzofuranil-piridopirazindionas novedosas”.
CL2020000471A1 (es) Regímenes de tratamiento.
UY31775A (es) Compuestos heterocíclicos como inhibidores de mek
AR116721A1 (es) Soluciones oromucosas de zolpidem o sales farmacéuticamente aceptables de los mismos
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
EA201791191A1 (ru) Водные фармацевтические композиции для местного применения в ротовой полости, содержащие флурбипрофен и декспантенол
AR079032A1 (es) Preparacion de un concentrado del factor h

Legal Events

Date Code Title Description
FB Suspension of granting procedure